Eli Lilly and Ramoxifumab is approved for gastric cancer in China

Lilly's vegFR2-targeted ramoxifumab has been approved for the second-line treatment of advanced gastric or gastroesophageal adenocarcinoma, according to the NMPA website. Remoxiumab is the first and to date the only second-line therapy approved for gastric/gastroesophageal junction cancer in the world.